image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.34
0 %
$ 256 M
Market Cap
-13.4
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CERS stock under the worst case scenario is HIDDEN Compared to the current market price of 1.34 USD, Cerus Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CERS stock under the base case scenario is HIDDEN Compared to the current market price of 1.34 USD, Cerus Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CERS stock under the best case scenario is HIDDEN Compared to the current market price of 1.34 USD, Cerus Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CERS

image
$2.2$2.2$2.1$2.1$2.0$2.0$1.9$1.9$1.8$1.8$1.7$1.7$1.6$1.6$1.5$1.5$1.4$1.4$1.3$1.3$1.2$1.2Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
180 M REVENUE
15.29%
-14.2 M OPERATING INCOME
52.67%
-21 M NET INCOME
44.09%
11.4 M OPERATING CASH FLOW
126.31%
-8.13 M INVESTING CASH FLOW
-94.27%
4.96 M FINANCING CASH FLOW
-53.49%
43.2 M REVENUE
-14.90%
-5.85 M OPERATING INCOME
-303.93%
-7.72 M NET INCOME
-201.25%
-844 K OPERATING CASH FLOW
-17.12%
-1.19 M INVESTING CASH FLOW
83.68%
1.07 M FINANCING CASH FLOW
43.57%
Balance Sheet Cerus Corporation
image
Current Assets 152 M
Cash & Short-Term Investments 80.5 M
Receivables 29.8 M
Other Current Assets 41.8 M
Non-Current Assets 48.9 M
Long-Term Investments 0
PP&E 15.5 M
Other Non-Current Assets 33.4 M
40.04 %14.82 %20.80 %7.73 %16.60 %Total Assets$200.9m
Current Liabilities 63.6 M
Accounts Payable 21.7 M
Short-Term Debt 21.6 M
Other Current Liabilities 20.3 M
Non-Current Liabilities 80.4 M
Long-Term Debt 64.9 M
Other Non-Current Liabilities 15.6 M
15.06 %14.98 %14.12 %45.04 %10.80 %Total Liabilities$144.0m
EFFICIENCY
Earnings Waterfall Cerus Corporation
image
Revenue 180 M
Cost Of Revenue 80.7 M
Gross Profit 99.5 M
Operating Expenses 114 M
Operating Income -14.2 M
Other Expenses 6.74 M
Net Income -21 M
200m200m150m150m100m100m50m50m00(50m)(50m)180m(81m)100m(114m)(14m)(7m)(21m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
55.21% GROSS MARGIN
55.21%
-7.89% OPERATING MARGIN
-7.89%
-11.60% NET MARGIN
-11.60%
-37.26% ROE
-37.26%
-10.41% ROA
-10.41%
-9.04% ROIC
-9.04%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Cerus Corporation
image
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -21 M
Depreciation & Amortization 1.86 M
Capital Expenditures -2.84 M
Stock-Based Compensation 22.9 M
Change in Working Capital 5.23 M
Others -3.46 M
Free Cash Flow 8.52 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Cerus Corporation
image
Wall Street analysts predict an average 1-year price target for CERS of $3.75 , with forecasts ranging from a low of $3 to a high of $5 .
CERS Lowest Price Target Wall Street Target
3 USD 123.88%
CERS Average Price Target Wall Street Target
3.75 USD 179.85%
CERS Highest Price Target Wall Street Target
5 USD 273.13%
Price
Max Price Target
Min Price Target
Average Price Target
555544443333222211Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 19
6. Ownership
Insider Ownership Cerus Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.25 M USD 5
6-9 MONTHS
64.2 K USD 2
9-12 MONTHS
267 K USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
2.93 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Cerus Corporation Celebrates World Blood Donor Day 2025 CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2025. In 2005, the World Health Assembly designated June 14th as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. This year's theme, “Give blood, give hope: together we save lives” is a reminder that hope is something we can all share. Cerus is proud to promote blood safety and exp. businesswire.com - 3 weeks ago
Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the management team are scheduled to present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, Florida, on Wednesday, June 11, 2025, at 8:40 a.m. Eastern Time. A live webcast of the presentation can be accessed via the Events & Presentation section of Cerus' Investor Relations website at ir.cerus.com. A replay of the webcast will be available on Cerus Investor Relati. businesswire.com - 1 month ago
Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced it will showcase the latest INTERCEPT Blood System clinical data at the 35th Regional International Society of Blood Transfusion (ISBT) Congress being held May 31 to June 4, 2025, in Milan. “The breadth of data being presented this year underscores the broad applicability of the INTERCEPT system for platelets, plasma, and cryoprecipitated fibrinogen complex as well as the potential benefit for red blood cells,” s. businesswire.com - 1 month ago
Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today two in-country regulatory approvals for INT200, one by the French National Agency for Medicines and Health Product Safety (ANSM) and the other by the Swiss Agency for Therapeutic Products (Swissmedic). The INT200, the Company's next generation LED-based illumination device, was developed as the new foundational platform for the INTERCEPT Blood System, with input and feedback from global customers to enhance daily. businesswire.com - 1 month ago
Cerus Corporation (CERS) Q1 2025 Earnings Call Transcript Cerus Corporation (NASDAQ:CERS ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Tim Lee - Head of Investor Relations Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moore - Senior Vice President Conference Call Participants Josh Jennings - TD Cowen Matt Park - Cantor Fitzgerald Vidyun Bais - BTIG Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation First Quarter 2025 Earnings Conference Call. seekingalpha.com - 2 months ago
Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates Cerus (CERS) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.05 per share a year ago. zacks.com - 2 months ago
Cerus Corporation Announces First Quarter 2025 Financial Results CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the first quarter ended March 31, 2025, and provided a business update. “We are off to a strong start in 2025, executing against our stated goals and making meaningful progress in advancing Cerus' mission to transform the safety and availability of transfused blood components,” said William “Obi” Greenman, Cerus' president and chief executive officer. “We delivered 13% first quarter product. businesswire.com - 2 months ago
Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025 CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2025 financial results will be released on Thursday, May 1, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Inv. businesswire.com - 2 months ago
Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200) CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood System for platelets and plasma under the European Union (EU) Medical Device Regulation (MDR). This approval allows Cerus to market the INT200 throughout the EU and in other regions that recognize the CE mark. Some countries may require additional in-country regulatory approval prior to commercializat. businesswire.com - 4 months ago
Cerus Corporation (CERS) Q4 2024 Earnings Call Transcript Cerus Corporation (NASDAQ:CERS ) Q4 2024 Earnings Call February 20, 2025 4:30 PM ET Company Participants Noopur Liffick - Investor Relations Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moore - Senior Vice President Conference Call Participants Joshua Jennings - TD Cowen Jacob Johnson - Stephens. Ross Osborn - Cantor Fitzgerald John Wilkin - Craig-Hallum Operator Good day, ladies and gentlemen. seekingalpha.com - 4 months ago
Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025 CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2024 financial results will be released on Thursday, February 20, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides,. businesswire.com - 4 months ago
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2024 and provided product revenue guidance for full-year 2025. The Company expects its preliminary full-year 2024 product revenue to be $180.3 million, exceeding the Company's 2024 product revenue guidance range of $177-$179 million. Included in the full-year preliminary 2024 product revenue results were $9.2 million of IFC revenue, representing gro. businesswire.com - 5 months ago
8. Profile Summary

Cerus Corporation CERS

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 256 M
Dividend Yield 0.00%
Description Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Contact 1220 Concord Avenue, Concord, CA, 94520 https://www.cerus.com
IPO Date Jan. 31, 1997
Employees 614
Officers Ms. Chrystal N. Jensen J.D. Chief Legal Officer, General Counsel & Secretary Ms. Carol M. Moore Senior Vice President of Regulatory Affairs, Quality & Clinical Mr. Vivek K. Jayaraman Chief Operating Officer Ms. Jessica Hanover Ph.D. Vice President of Corporate Affairs Lainie Corten Vice President of Global Marketing Mr. William M. Greenman President, Chief Executive Officer & Director Mr. Kevin D. Green CPA Vice President of Finance & Chief Financial Officer Dr. Laurence M. Corash M.D. Co-Founder & Chief Scientific Officer Dr. Nina Mufti Ph.D. Senior Vice President of Research & Development Dr. Richard J. Benjamin MBChB, Ph.D. Chief Medical Officer